Francis B. Palumbo
Affiliations: | University of Maryland School of Medicine, Baltimore, MD, United States |
Area:
Pharmacy, Health Care ManagementGoogle:
"Francis Palumbo"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Khoruts A, Hoffmann DE, Palumbo FB. (2019) The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation. The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics. 47: 482-504 |
| Moyo P, Simoni-Wastila L, Griffin BA, et al. (2019) Prescription drug monitoring programs: Assessing the association between "best practices" and opioid use in Medicare. Health Services Research |
| Khokhar B, Park JY, Kiptanui Z, et al. (2018) Assessing Physician and Patient Perceptions of Generic Drugs via Facebook: A Feasibility Study: The Journal of Pharmacy Technology. 34: 43-47 |
| Hoffmann D, Palumbo F, Ravel J, et al. (2017) Improving regulation of microbiota transplants. Science (New York, N.Y.). 358: 1390-1391 |
| Moyo P, Simoni-Wastila L, Griffin BA, et al. (2017) Impact of prescription drug monitoring programs (pdmps) on opioid utilization among medicare beneficiaries in 10 u.s. States. Addiction (Abingdon, England) |
| Wei YJ, Palumbo FB, Simoni-Wastila L, et al. (2015) Relationships between antiparkinson medication nonadherence, regimen modifications, and healthcare utilization and expenditures. Parkinsonism & Related Disorders. 21: 36-41 |
| Wei YJ, Palumbo FB, Simoni-Wastila L, et al. (2014) Antiparkinson drug adherence and its association with health care utilization and economic outcomes in a Medicare Part D population. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: 196-204 |
| Wei YJ, Palumbo FB, Simoni-Wastila L, et al. (2013) Antiparkinson drug use and adherence in medicare part D beneficiaries with parkinson's disease Clinical Therapeutics. 35: 1513-1525 |
| Williams EO, Stock EM, Zeber JE, et al. (2012) Payer types associated with antipsychotic polypharmacy in an ambulatory care setting Journal of Pharmaceutical Health Services Research. 3: 149-155 |
| Roberts C, Palumbo FB. (2011) The "treatment IND (investigational new drugs)": public policy considerations. Journal of Pharmaceutical Marketing & Management. 3: 41-59 |